Details for Patent: 10,590,102

Which drugs does patent 10,590,102 protect, and when does it expire?

Patent 10,590,102 protects COTELLIC and is included in one NDA.

Protection for COTELLIC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in thirty-six countries.

Summary for Patent: 10,590,102

Title:	Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Abstract:	This disclosure relates to the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone. The disclosure also relates to pharmaceutical compositions comprising the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone. The disclosure also relates to methods of treating cancers comprising administering to a patient in need thereof the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone.
Inventor(s):	Adrian St. clair Brown
Assignee:	Johnson Matthey PLC , Exelixis Inc
Application Number:	US15/852,280
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,590,102

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	COTELLIC	cobimetinib fumarate	TABLET;ORAL	206192-001	Nov 10, 2015		RX	Yes	Yes					Y

International Family Members for US Patent 10,590,102

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	105483
Australia	2016288209
Australia	2021200202
Brazil	112017028516
Canada	2990222
Chile	2017003475